FRONT PHARMACOL 润色咨询

Frontiers in Pharmacology

出版年份:暂无数据 年文章数:13176 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:6.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2026-09-04 ms1000001131168263 来自河北省

    这个杂志在哪里上传cover letter 啊?没找到啊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2026-07-17 ms1000000602711228 来自福建省

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向:Meta分析
    经验分享:17天录用。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2026-07-17 ms1000000602711228 来自福建省

    偏重的研究方向:Meta分析;胃肠
    经验分享:17天录用😍

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2025-12-06 ms4000001095367238 来自吉林省

    审稿速度:3.0 | 投稿命中率:95.0
    偏重的研究方向:药理学
    经验分享:中了,但是分区降为三区了,老板不让投

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2025-05-31 ms6000002977722155 来自上海

    相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。
    最新影响因子​​:4.4(2023 JCR)
    ​​中科院分区​​:大类医学2区,小类药学2区
    ​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等
    ​​OA模式​​:是,需支付版面费
    投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月
    2-4周送审后需邀请2位以上审稿人。

    4

    展开4条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2025-10-12 ms8000002977722174 来自上海

    投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。
    如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2025-03-23 小白白心态要稳 来自辽宁省

    想撤稿,应该如何操作呀

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2025-03-17 ms5000002977722150 来自上海

    偏重的研究方向:中药
    经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑
    从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。
    有跟我一样的朋友吗,大家一起来交流一下。

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2022-07-17 ms7000001549986178

    想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?

    6

    展开6条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2363812, encodeId=2a302363812b0, content=这个杂志在哪里上传cover letter 啊?没找到啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d4215515377, createdName=ms1000001131168263, createdTime=Fri Sep 04 13:06:21 CST 2026, time=2026-09-04, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2344048, encodeId=0e5623440487d, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向:Meta分析<br>经验分享:17天录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:47:01 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2344047, encodeId=6eec234404e48, content=偏重的研究方向:Meta分析;胃肠<br>经验分享:17天录用😍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d49c8319099, createdName=ms1000000602711228, createdTime=Fri Jul 17 07:46:20 CST 2026, time=2026-07-17, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2292158, encodeId=083b229215829, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:药理学<br>经验分享:中了,但是分区降为三区了,老板不让投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fb79699195, createdName=ms4000001095367238, createdTime=Sat Dec 06 18:57:09 CST 2025, time=2025-12-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2267516, encodeId=95d8226e516c2, content=相关期刊内容分享给大家,如有不对的地方欢迎纠正,一起交流学习。<br>最新影响因子​​:4.4(2023 JCR)<br>​​中科院分区​​:大类医学2区,小类药学2区<br>​​收录数据库​​:SCI-E、PubMed、Scopus、DOAJ等<br>​​OA模式​​:是,需支付版面费<br>投稿中一般1–4周就可以分配编辑,但是25存在延迟的情况,我看很多人稿件卡在“Editorial Assignment”超1个月<br>2-4周送审后需邀请2位以上审稿人。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms6000002977722155, createdTime=Sat May 31 22:26:33 CST 2025, time=2025-05-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2284519, encodeId=d0f42284519d5, content=投稿前务必在官网确认清楚,避免投错方向导致编辑分配延迟。<br>如果研究是生信 + 实验 结合,需在Cover Letter强调实验验证部分,纯生信稿无体外实验易初审拒稿,感觉很多人都会忽略这一点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms8000002977722174, createdTime=Sun Oct 12 23:29:12 CST 2025, time=2025-10-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2257407, encodeId=120c225e40762, content=想撤稿,应该如何操作呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6e762538727, createdName=小白白心态要稳, createdTime=Sun Mar 23 18:17:51 CST 2025, time=2025-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2256513, encodeId=928a22565139c, content=偏重的研究方向:中药<br>经验分享:投稿一个月了还在ea,一直没有分配编辑,焦虑<br>从评论区了解到该期刊的平均审稿周期是14周,个人觉得还是比较长的。<br>有跟我一样的朋友吗,大家一起来交流一下。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Mon Mar 17 23:15:17 CST 2025, time=2025-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1232891, encodeId=1d7912328916e, content=想问一下大家稿件停留在了Editorial Assignment阶段,已经三周了,编辑处显示了我选择编辑的名字,但是一直没有进展,我如果要给编辑发邮件的话,是通过Frontier的投稿官网页面给他发,还是找到编辑的邮箱私下询问呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=271, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230107/08d7227584d8419e9fc6eb0769470af8/651a32af4be94530b72739b0aea8ba0c.jpg, createdBy=ceb35641108, createdName=ms7000001549986178, createdTime=Sun Jul 17 00:40:05 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2254108, encodeId=bda02254108c7, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;天然化合物;耐药<br>经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?<br>Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.<br><br>Please take action by 16 Mar 2025 on this request to either:<br><br>resubmit the manuscript, or<br>contact the editorial office., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce935708129, createdName=ms6000001686001327, createdTime=Sat Mar 01 16:25:55 CST 2025, time=2025-03-01, status=1, ipAttribution=上海)]
    2025-03-01 ms6000001686001327 来自上海

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤;天然化合物;耐药
    经验分享:请问投稿后遇到让重新提交的,是什么情况呢?是差什么材料,还是格式有问题吗?
    Editorial Office Frontiers in Pharmacology Editorial Office requested resubmission of your manuscript.

    Please take action by 16 Mar 2025 on this request to either:

    resubmit the manuscript, or
    contact the editorial office.

    1

    展开1条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分